Source-grounded facts extracted from Petros Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Petros Pharmaceuticals, Inc. engaged HTL International, LLC as its auditor.
“On August 29, 2025, the Committee engaged HTL International, LLC (“HTL”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, effective immediately.”
Petros Pharmaceuticals, Inc. dismissed CBIZ CPAs P.C. as its auditor.
“On August 29, 2025, the Audit Committee of the Board of Directors (the “Committee”) of Petros Pharmaceuticals, Inc. (the “Company”) approved the dismissal of CBIZ CPAs P.C. (“CBIZ CPAs”) as the Company’s independent registered public accounting firm, effective as of the same date.”
Petros Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1), 5550(a)(2), 5810(c)(3)(A)(iii), 5810(d)).
“May 20, 2025, Petros Pharmaceuticals, Inc. (the “Company”) received a letter (the “Letter”) from the Nasdaq Hearings Panel (the “Panel”) indicating that the Panel has determined to delist the Company’s securities from The Nasdaq Stock Market LLC (“Nasdaq”) as a result of (i) the Company’s failure to maintain compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), (ii) the Company’s failure to meet the minimum bid price of $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2), (iii) the Company’s low bid price pursuant to Nasdaq Listing Rule 5810(”
Petros Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other (rules 5810(c)(3)(A)(iii), 5810(d)).
“April 28, 2025, Nasdaq notified the Company (the “ Notice ”) it had public interest concerns regarding the Company’s public offering of securities that closed on February 19, 2025, which serves as an additional basis for delisting the Company’s securities pursuant to Nasdaq Listing Rule 5810(d). The Company intends to address these concerns before a Nasdaq Hearings Panel (the “ Panel ”). As a result of the Company’s hearing request pending appeal notice, all delisting actions have been stayed, pending a hearing before the Panel. The Notice has no immediate impact on the Company’s common stock”
Petros Pharmaceuticals, Inc.: Increased authorized shares of Common Stock from 250,000,000 to 7,000,000,000 and made a corresponding change to total authorized capital stock shares (effective 2025-04-11).
“the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Share Increase Amendment”) to increase the number of authorized shares of the Common Stock from 250,000,000 shares to 7,000,000,000”
Greg Bradley resigned as director at Petros Pharmaceuticals, Inc..
“On October 2, 2024, Greg Bradley, who served as a member of the Board tendered his resignation from his role as director of the Company, effective as of October 2, 2024.”
John Shulman resigned as director at Petros Pharmaceuticals, Inc..
“On October 1, 2024, John Shulman, who served as a member of the board of directors (the “Board”) of Petros Pharmaceuticals, Inc. (the “Company”), tendered his resignation from his role as director of the Company, effective as of October 1, 2024.”
Petros Pharmaceuticals, Inc. amended Omnibus Waiver and Amendment with the Investors (effective 2023-12-31).
“On March 21, 2024, the Company entered into an Omnibus Waiver and Amendment (the “Waiver and Amendment”) with the Investors, effective as of December 31, 2023.”
Petros Pharmaceuticals, Inc. engaged Marcum LLP as its auditor.
“On January 8, 2024, the Audit Committee engaged Marcum LLP (“Marcum”) as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2023, effective immediately.”
Petros Pharmaceuticals, Inc. dismissed EisnerAmper LLP as its auditor.
“On January 8, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of Petros Pharmaceuticals, Inc. (the “Company”) dismissed EisnerAmper LLP (“EisnerAmper”) as the Company’s independent registered public accounting firm, effective immediately.”
Petros Pharmaceuticals, Inc. shareholders approved Approval, on an advisory basis, of the compensation paid to the Company's named executive officers at the 2023-12-29 meeting.
“For Against Abstain Broker Non-Votes 735,195 30,435 4,208 506,053”
Petros Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-12-29 meeting.
“For Against Abstain 1,181,138 91,884 2,869”
Petros Pharmaceuticals, Inc. shareholders approved Election of the five directors named in the Proxy Statement to the Board of Directors at the 2023-12-29 meeting.
“Nominee For Against Abstain Broker Non-Votes John D. Shulman 741,470 13,235 15,133 506,053”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.